Anti Xa Levels - Neonatal Disorders

Relevant Publications

\'Door-to-prophylaxis\' as a novel quality improvement metric in prevention of venous thromboembolism following traumatic injury.

Issue Release: 2024

Pharmacologic Venous Thromboembolism Prophylaxis in Patients with Nontraumatic Subarachnoid Hemorrhage Requiring an External Ventricular Drain.

Issue Release: 2024

Does in vitro hemolysis affect measurements of plasma apixaban concentration by UPLC-MS and anti-Xa assay?

Issue Release: 2024

Monitoring anti-Xa levels in elderly medical patients undergoing thromboprophylaxis: A prospective cohort study.

Issue Release: 2024

Plasma apixaban concentrations and thrombin generation assay parameters in response to dose reduction for atrial fibrillation.

Issue Release: 2024

Heparanase inhibitor improves clinical study in patients with septic cardiomyopathy.

Issue Release: 2024

Elevated Anti-Xa in the Setting of Prophylactic Unfractionated Subcutaneous Heparin Administration.

Issue Release: 2024

[Implementation of edoxaban anti-Xa activity assay in a hospital laboratory and evaluation of its analytical performance].

Issue Release: 2024

A systematic review of therapeutic enoxaparin dosing in obesity.

Issue Release: 2024

Anticoagulation with argatroban using hemoclot™ targets is safe and effective in CARDS patients receiving venovenous extracorporeal membrane oxygenation: An exploratory bi-centric cohort study.

Issue Release: 2024

Enoxaparin thromboprophylaxis in hospitalized obese pediatric patients.

Issue Release: 2024

Prophylactic Enoxaparin Dosing Using Anti-Factor Xa Levels in Hepatic Surgery Patients: A Pilot Study.

Issue Release: 2024

Thrombosis prophylaxis following trauma.

Issue Release: 2024

Efficacy and Safety of Tinzaparin Thromboprophylaxis in Lung Cancer Patients with High Thromboembolic Risk: A Prospective, Observational, Single-Center Cohort Study.

Issue Release: 2024

Antithrombin levels and heparin responsiveness during veno-arterial extracorporeal membrane oxygenation: a prospective single-center cohort study.

Issue Release: 2024

Pilot study examining anti-factor Xa levels for heparin monitoring and outcomes in patients with cerebral venous thrombosis.

Issue Release: 2024

Retrospective study evaluating safety, clinical effect, and dosing of dalteparin for the treatment of venous thromboembolism in term neonates.

Issue Release: 2024

How enoxaparin underdosing and sex contribute to achieving therapeutic anti-Xa levels.

Issue Release: 2024

Anti factor Xa monitoring for venous thromboprophylaxis in severely burn-injured patients: A systematic review.

Issue Release: 2024

FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription.

Issue Release: 2024

What is a Hearing Screen?

When Should Ultrasound be Used?

Why is Exclusive Breastfeeding Important?

What are the Indications for Sulfasalazine in Pediatrics?

How Can Feeding Skills Be Assessed?

What Are the Benefits of Having Strong Credentials?

What Does a Normal Result Look Like?

How Should Pediatricians Approach Contraceptive Counseling?

Where Can I Learn Pediatric CPR?

Why Should Raw or Undercooked Fish and Water Plants Be Avoided?

Partnered Content Networks

Relevant Topics